Med. praxi. 2026;23(4):259-262 [Neurol. praxi. 2026;27(4):291-294]

Mild cognitive impairment in the era of biological therapy: the importance of early intervention

MUDr. Jiří Cerman, Ph.D.¹, MUDr. Ing. Klára Knápková², prof. MUDr. Jakub Hort, Ph.D., FEAN¹

¹ Neurologická klinika UK, 2. LF a FN Motol a Homolka, Praha

² Psychiatrická nemocnice Bohnice, Praha

Mild cognitive impairment (MCI) is a heterogeneous clinical syndrome that is currently gaining attention due to the advent of new biological treatments for Alzheimer’s disease. Although these therapies open up new possibilities for causal intervention, their use in real-world practice remains limited to a relatively narrow group of patients for whom this treatment is appropriate. This article summarizes current options for the management of MCI in routine clinical practice and focuses primarily on rational approaches to early intervention in patients who are not candidates for biologic therapy.

Keywords: mild cognitive impairment (MCI), Alzheimer’s disease, EGb 761, biomarkers, amyloid beta, tau protein, neuroprotection, early intervention

Published: October 14, 2026  Show citation